STALLERGENES : Strong Business Growth: +17% and Earnings Per Sh...( PARIS August 28 /- The Board of D...)

PARIS, August 28 /PRNewswire-FirstCall/ -- The Board of Directors, meeting on 28 August 2007, under the chairmanship of Albert Saporta approved the consolidated financial statements at 30 June 2007:

(EUR millions) 2007 % of 2006 % of % change

HY1 sales HY1 sales 2007/2006

Sales 74.8 100.0 64.2 100.0 17

Cost of sales (16.9) (22.5) (14.6) (22.7) 16

Gross profit 57.9 77.5 49.6 77.3 17

General, (31.3) (41.9) (28.0) (43.6) 12

administrative and

selling expenses

Gross operating profit 26.6 35.6 21.6 33.7 23

before R&D

R&D (11.2) (15.0) (9.4) (14.6) 19

Operating profit 15.4 20.6 12.2 19.1 26

Net profit (Group 10.1 13.6 7.7 12.0 32

share)

Net earnings per share 0.76 0.59 30

(diluted, in EUR)

Net borrowings 9.3 (16%) 13.3 (29%) (30)

(gearing)

2007 1st half-year registered a marked improvement in operating profitability

Operating profit (up 26%) fully benefited from the sharp growth in sublingual route sales (up 21%), a segment in which Stallergenes consolidated its leadership and strategic positioning. Net profit increased by 32% to EUR 10.1 million. Net borrowings were down 30%.

International roll-out of operations

The 1st half-year represents a major milestone in the Group's international development: incorporation of Stallergènes BV in Holland, active preparation of the ORALAIR(R) Grasses tablet registration in Canada, operational rollout in the East of the European Union (Austria, Slovenia and Romania).

Outlook

The Company remains confident in the registration of ORALAIR Grasses in Germany at the end of 2007 and in the initialisation of the m
'/>"/>